MEN’S HEALTH RESEARCH AND INNOVATION
Utah Men’s Health not only offers cutting edge treatment for men’s health conditions, but we also pride ourselves on conducting bleeding-edge research and innovation in men’s health, engaging in clinical and laboratory research, running clinical trials, and working on medical devices and new treatments for the conditions that we treat. Our research and innovation efforts help to further set us apart from the pack, as we are constantly working to better understand disease and to figure out better ways to treat it.
Dr. Hotaling is a NIH-funded physician-scientist and entrepreneur. His research efforts examine all facets of men’s health with an emphasis on male infertility and erectile dysfunction. He works closely with Dr. Pastuszak and the rest of the research team in Men’s Health at the University of Utah. He serves on the editorial boards of Fertility & Sterility, The Journal of Assisted Reproduction and Genetics and Urology Times.
Dr. Hotaling’s work has examined the relationship between male infertility and individual and familial health. Specifically, his work has demonstrated that men with male infertility may be more likely to have certain chronic health issues and that this risk may extend to their family. Additionally, he has examined the role of hormone management and the use of clomiphene citrate in men with infertility publishing some of the largest series of these patients available in the literature. He has also published seminal articles in top tier journals demonstrating how male infertility may be a biomarker for individual and familial health.
Dr. Hotaling laboratory efforts are in conjunction with Dr. Brad Cairns, Dr. Doug Carrell and Dr. Jingtao Guo to help profile human spermatogonial stem cells with the ultimate goal of translating these advances to help improve patient care for infertile men. This work has been published in Cell Stem Cell and Cell Research, which are both top tier journals, and has formed the basis of several large grant applications.
Dr. Hotaling also has a large NIH grant to study the genetics of erectile dysfunction. This work was published in the journal Proceedings of the National Academy of Science in 2018 after the team found a gene, SIM1, which is associated with erectile dysfunction. Dr. Hotaling serves as a principal investigator on this grant, one of the few grants in the country that focuses on ED.
Dr. Hotaling has founded 3 different companies. Two of these three companies have received multi-million dollar NIH grants. The 3 companies are listed below
- StreamDx is a point-of-care urine flow device to help patients with BPH. It recently registered with the FDA, has 5 full time employees and will have a device on the market in the near future. It was founded by Dr. Hotaling in 2014.
- Andro360 is a point of care erectile dysfunction monitoring device that can be worn around the penis. This company has a part time CEO and COO and is based in San Diego. Hotaling founded Andro360 in 2012
- Nanonc is a microfluidic based sperm sorting device that was founded out of the andrology lab at the University of Utah. It has developed a novel microfluidic chip that can sort sperm for artificial insemination or in vitro
- MiOx sperm oxidation profiling in men with and without varicoceles
- Folic Acid and Zinc Supplementation Trial (FAZST) completed
- Understanding the population scale relationship between male infertility and somatic health
- Understanding the genetic and epigenetic factors driving the relationship of male infertility and somatic health
- Developing a complete expression profile of tissue from men with erectile dysfunction
- Determining what genetic factors contribute to risk of erectile dysfunction
- Developing novel techniques and diagnostics to treat severe male factor infertility
- Understanding the long term impact of chemotherapy on fertility
Dr. Pastuszak is a NIH-funded physician-scientist and entrepreneur. His research efforts examine all facets of men’s health, with an emphasis on Peyronie’s disease and male infertility. He works closely with Dr. Hotaling and the rest of the research team in Men’s Health at the University of Utah. Dr. Pastuszak serves on the Editorial Boards of the Journal of Sexual Medicine, Sexual Medicine Reviews, Fertility & Sterility, and the Asian Journal of Andrology.
Dr. Pastuszak’s clinical research has examined the role of testosterone in male physiology and prostate cancer, the pathophysiology and treatment of male infertility, the relationship between Peyronie’s disease and other medical conditions, and cost, distance, and treatment factors for patients with Peyronie’s disease. Dr. Pastuszak is also currently studying the impact of social media on men’s health, and utilizing “big data” to examine the genetic and familial nature of Peyronie’s disease and other superficial fibrosing disorders, as well as other facets of men’s health. Dr. Pastuszak’s laboratory research efforts focus on the genetic factors and molecular mechanisms that lead to Peyronie’s disease as well as the molecular mechanisms of male infertility.
Dr. Pastuszak currently has NIH funding to study Peyronie’s disease, and has received numerous other grants and awards to move his work forward, including the Urology Care Foundation Research Scholars Award and most recently a Urology Care Foundation Rising Stars in Urology Award.
Dr. Pastuszak is also the founder of Woven Health, a digital health company that develops mobile and web-based collaboration and communication software for patient care teams, and is a co-founder of Morph Athletics, a company focusing on novel products for genital and body protection.
- Determination of the familiarity of Peyronie’s disease and other superficial fibrosing disorders
- Determination of genetic factors that predispose to Peyronie’s disease and other superficial fibrosing disorders
- Understanding the molecular mechanisms of Peyronie’s disease
- Understanding the molecular mechanisms of male infertility
- Understanding the relationship between Peyronie’s disease and other superficial fibrosing disorders and other benign and malignant conditions
- Determining the factors driving treatment selection for Peyronie’s disease
- Understanding the physiology and interventions in hypogonadism
- The role of extracorporeal shockwave therapy in the management of erectile dysfunction